Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis With Non-F508del CFTR Genotypes
NCT05331183Phase 3Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of elexacaftor, tezacaftor, ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Nov 2022; status: active, not recruiting.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05331183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05331183.